



# Pluvicto in Saudi Arabia

*The SFDA named-patient coordination pathway — indicative 2026*

ONCOLOGY · PSMA-POSITIVE MCRPC

## The clinical situation

Pluvicto (lutetium Lu-177 vipivotide tetraxetan) is an FDA-approved radioligand therapy that delivers targeted beta-radiation to PSMA-expressing prostate cancer cells, indicated for metastatic castration-resistant prostate cancer after progression on androgen-receptor pathway inhibitors and taxane chemotherapy. Manufactured by Novartis. Because Pluvicto is a short-half-life radiopharmaceutical, it must ship against a tight decay calendar and can only be administered at a radiation-licensed nuclear medicine facility.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating oncologist confirms PSMA-PET eligibility and documents a written clinical rationale and prior line history.
- 2 Nuclear medicine facility confirmed.** A Saudi facility with radiation-handling licensure (Riyadh, Jeddah, or Eastern Province tertiary centres) accepts the case.
- 3 SFDA named-patient application.** Clinical rationale, patient reference, product details, and chain-of-custody plan are filed; coordination with the Nuclear & Radiological Regulatory Commission.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner, booked to your administration date.
- 5 Arrival & administration.** The facility receives the dose under radiation-compliant handling and administers under your oncologist's care; subsequent cycles typically at 6-week intervals.

### Indicative economics

**Reference US cash-pay range:** USD 45,000–50,000 per dose; typical course 4–6 doses. Radiation logistics, SFDA documentation, and concierge coordination are incremental. Full transparent quote at intake.

### Indicative first-dose timing

**14–28 days** from a complete SFDA application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and SFDA review. **Logistics.** Radiation-compliant, temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist and the administering nuclear medicine facility.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Pluvicto × Saudi Arabia first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/pluvicto-saudi-arabia.html](https://reservemed.com/access-guides/pluvicto-saudi-arabia.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team